Bristol-myers Squibb Company Profile
✉ Email this page to a colleague
What is the competitive landscape for BRISTOL-MYERS SQUIBB, and when can generic versions of BRISTOL-MYERS SQUIBB drugs launch?
BRISTOL-MYERS SQUIBB has one approved drug.
There are five US patents protecting BRISTOL-MYERS SQUIBB drugs.
There are eighty-one patent family members on BRISTOL-MYERS SQUIBB drugs in thirty-one countries and nineteen supplementary protection certificates in sixteen countries.
Summary for Bristol-myers Squibb
International Patents: | 81 |
US Patents: | 5 |
Tradenames: | 1 |
Ingredients: | 1 |
NDAs: | 1 |
Patent Litigation for Bristol-myers Squibb: | See patent lawsuits for Bristol-myers Squibb |
PTAB Cases with Bristol-myers Squibb as patent owner: | See PTAB cases with Bristol-myers Squibb as patent owner |
Drugs and US Patents for Bristol-myers Squibb
International Patents for Bristol-myers Squibb Drugs
Country | Patent Number | Estimated Expiration |
---|---|---|
South Korea | 20090040909 | ⤷ Try a Trial |
Australia | 2007286222 | ⤷ Try a Trial |
Norway | 2017036 | ⤷ Try a Trial |
European Patent Office | 2183244 | ⤷ Try a Trial |
China | 101558059 | ⤷ Try a Trial |
Peru | 20080542 | ⤷ Try a Trial |
Eurasian Patent Organization | 201000196 | ⤷ Try a Trial |
>Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for Bristol-myers Squibb Drugs
Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
---|---|---|---|---|
2049522 | C20150003 00128 | Estonia | ⤷ Try a Trial | PRODUCT NAME: DAKLATASVIIR;REG NO/DATE: EU/1/14/939 26.08.2014 |
2049522 | 9/2015 | Austria | ⤷ Try a Trial | PRODUCT NAME: DECLATASVIR; REGISTRATION NO/DATE: EU/1/14/939 (MITTEILUNG) 20140826 |
2049522 | 1590007-9 | Sweden | ⤷ Try a Trial | PRODUCT NAME: DACLATASVIR AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF, ESPECIALLY DACLATASVIR DIHYDROCHLORIDE; REG. NO/DATE: EU/1/14/939 20140826 |
2049522 | SPC/GB15/003 | United Kingdom | ⤷ Try a Trial | PRODUCT NAME: DACLATASVIR AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF, ESPECIALLY DACLATASVIR DIHYDROCHLORIDE; REGISTERED: UK EU/1/14/939/001-004 20140826 |
2049522 | C300713 | Netherlands | ⤷ Try a Trial | PRODUCT NAME: DACLATASVIR EN FARMACEUTISCH; REGISTRATION NO/DATE: EU/1/14/939/001-004 20150119 |
2049522 | C 2015 003 | Romania | ⤷ Try a Trial | PRODUCT NAME: DACLATASVIR SI SARURILE ACCEPTABILE FARMACEUTIC ALEACESTUIA, IN SPECIAL DACLATASVIR DICLORHIDRAT; NATIONAL AUTHORISATION NUMBER: EU/1/14/939/001, EU/1/14/939/002, EU/1/14/939/003, EU/1/14/939/004; DATE OF NATIONAL AUTHORISATION: 20140822; NUMBER OF FIRST AUTHORISATION IN EUROPEAN ECONOMIC AREA (EEA): EU/1/14/939/001, EU/1/14/939/002, EU/1/14/939/003, EU/1/14/939/004; DATE OF FIRST AUTHORISATION IN EEA: 20140822 |
2049522 | C02049522/01 | Switzerland | ⤷ Try a Trial | ADRESSAENDERUNG |
>Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Here is a list of applicants with similar names.